Kala Bio Inc Reports Results For The Quarter Ended June 30: Earnings Summary
08/08/2025 15:06
KALA BIO Inc KALA.OQ reported a quarterly adjusted loss of $1.71 per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-3.16. The mean expectation of two analysts for the quarter was for a loss of $1.70 per share. Wall Street expected results to range from $-2.54 to $-1.52 per share. Reported revenue was zero; analysts expected zero. KALA BIO Inc's reported EPS for the quarter was a loss of $1.41. The company reported a quarterly loss of $11.16 million. KALA BIO Inc shares had risen by 50.4% this quarter and gained 3.2% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 3.8% in the last three months. In the last 30 days, one analyst negatively revised an earnings estimate RECOMMENDATIONS The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy." Wall Street's median 12-month price target for KALA BIO Inc is $12.00, about 40.3% above its last closing price of $7.16 This summary was machine generated from LSEG data August 8 at 02:06 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -1.70 | -1.41 | Beat |
| Mar. 31 2025 | -2.03 | -1.41 | Beat |
| Sep. 30 2024 | -2.28 | -1.74 | Beat |
| Sep. 30 2024 | -2.43 | -3.16 | Missed |